Skip to content

Study to assess the plasma concentration of rilzabrutinib given as a tablet to adult participants with severe renal impairment compared to matched participants with normal renal function

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525707-27-00
Enrollment
8
Registered
2026-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Impairment

Interventions

None listed

Sponsors

Sanofi-Aventis Recherche & Developpement
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 31, 2026